Pentixapharm Holding AG (ETR:PTP)

BRIEF

published on 05/27/2025 at 09:48, 8 months 9 days ago

Pentixapharm Unveils New Clinical Development Strategy

Oncology Pentixapharm CXCR4 Trials Theranostic Strategy Hematologic Malignancies
BRIEF

published on 05/27/2025 at 09:48, 8 months 9 days ago

Pentixapharm dévoile une nouvelle stratégie de développement clinique

Oncologie Pentixapharm Essais CXCR4 Stratégie Théranostique Hémopathies Malignes
PRESS RELEASE

published on 05/27/2025 at 09:43, 8 months 9 days ago

EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Pentixapharm outlines new clinical development strategy focusing on CXCR4 therapeutic and diagnostic oncology programs, discontinuing PTF301 trial in MZL, preparing new trials in hematologic malignancies and Bladder Cancer

Pentixapharm CXCR4 Oncology Programs Clinical Development Strategy Theranostic Precision
BRIEF

published on 04/25/2025 at 15:44, 9 months 10 days ago

Pentixapharm présentera son anticorps innovant GT-008 à l'AACR 2025

Thérapie Contre Le Cancer Pentixapharm Anticorps GT-008 Glycane-dépendant Ciblage CD24
BRIEF

published on 04/25/2025 at 15:44, 9 months 10 days ago

Pentixapharm to Showcase Innovative Antibody GT-008 at AACR 2025

Cancer Therapy Pentixapharm GT-008 Antibody Glycan-Dependent CD24 Targeting
PRESS RELEASE

published on 04/25/2025 at 15:39, 9 months 10 days ago

Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025
Pentixapharm to present novel CD24 antibody GT-008 for solid tumors at AACR 2025, showcasing glycan-dependent mechanism for targeted therapy

Solid Tumors Pentixapharm AACR 2025 GT-008 CD24 Antibody
BRIEF

published on 04/24/2025 at 14:05, 9 months 11 days ago

Pentixapharm Signs Manufacturing Deal for Yttrium-90 Therapy

Clinical Trials Eckert & Ziegler Radiopharmaceuticals Pentixapharm Yttrium-90
BRIEF

published on 04/24/2025 at 14:05, 9 months 11 days ago

Pentixapharm signe un accord de fabrication pour la thérapie à l'yttrium-90

Eckert & Ziegler Essais Cliniques Produits Radiopharmaceutiques Pentixapharm Yttrium-90
PRESS RELEASE

published on 04/24/2025 at 14:00, 9 months 11 days ago

Pentixapharm Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE
Pentixapharm signs manufacturing agreement for Yttrium-90-based PentixaTher with Eckert & Ziegler SE to produce CXCR4-targeting radiotherapeutic doses for clinical trials

Clinical Trials Eckert & Ziegler SE Pentixapharm Y90-PentixaTher Radiotherapeutic
BRIEF

published on 04/15/2025 at 08:22, 9 months 20 days ago

Pentixapharm Holding AG publie ses résultats financiers pour 2024 et ses perspectives pour 2025

Recherche Et Développement Résultats Financiers 2024 Prévisions Financières 2025 Innovation Radiopharmaceutique Stratégie Pentixapharm

Published on 02/05/2026 at 16:40, 2 minutes ago

Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 57 minutes ago

American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report
Published on 02/05/2026 at 15:10, 1 hour 32 minutes ago

Electric Metals (USA) Limited Announces Change of Auditor
Published on 02/05/2026 at 14:50, 1 hour 52 minutes ago

High Tide Resources Announces Non-Brokered Private Placements
Published on 02/05/2026 at 14:30, 2 hours 12 minutes ago

Electrovaya Announces Date for Q1-2026 Financial Results & Conference Call

View all ACCESSWIRE

Published on 02/05/2026 at 16:30, 12 minutes ago

Dividend Declaration
Published on 02/05/2026 at 16:20, 21 minutes ago

Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 02/05/2026 at 16:20, 21 minutes ago

Birla Carbon Launches New Continua™ SCM Production Line in Italy
Published on 02/05/2026 at 15:56, 45 minutes ago

Original-Research: Verve Group SE (von First Berlin Equity Research GmbH): Kaufen
Published on 02/05/2026 at 15:40, 1 hour 2 minutes ago

BIKE24 exceeds revenue and earnings forecast for fiscal year 2025 – strong growth in the fourth quarter

View all EQS

Published on 02/05/2026 at 16:35, 6 minutes ago

Voting rights
Published on 02/05/2026 at 16:35, 6 minutes ago

Droits de vote
Published on 02/05/2026 at 16:04, 38 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 02/05/2026 at 16:02, 39 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
Published on 02/05/2026 at 11:30, 5 hours 12 minutes ago

Déclaration nombre d'actions et droits de vote - 05.02.2026

View all LES ECHOS COMFI WIRE

News